Epoetin alfa biosimilar - Dragon PharmaceuticalAlternative Names: BR 05001; Recombinant human erythropoietin - Dragon Pharmaceutical
Latest Information Update: 26 Feb 2016
At a glance
- Originator Dragon Pharmaceutical
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 15 Oct 2001 Dragon Pharmaceutical enters into a licensing agreement with Boryung Pharmaceutical for marketing and distribution in Korea (Dragon Pharmaceutical 8-K, October 2001) before October 2001